Genesis Molecular AI Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
170
- Latest Deal Type
-
Later Stage VC
- (Announced)
- Latest Deal Amount
-
$120M
- Investors
-
23
Genesis Molecular AI General Information
Description
Developer of artificial intelligence-driven drug discovery technology designed to accelerate the identification and development of small molecule medicines. The company's technology integrates generative AI models with computational chemistry and iterative, interdisciplinary research workflows to design, evaluate, and optimize small molecule drug that drives the discovery and development of novel molecule drugs to treat patients suffering from severe and debilitating diseases, enabling the medical community to upgrade and optimize patient clinical outcomes.
Contact Information
Website
www.genesis.mlCorporate Office
- 101 South Ellsworth Avenue
- Suite 450
- San Mateo, CA
- United States
Corporate Office
- 101 South Ellsworth Avenue
- Suite 450
- San Mateo, CA
- United States
Genesis Molecular AI Timeline
Genesis Molecular AI Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC | 20-May-2026 | $120M | Announced | Generating Revenue | ||
| 5. Later Stage VC | 13-Nov-2024 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series B) | 25-Aug-2023 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A2) | 26-Aug-2022 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 24-Nov-2020 | $52M | $56.1M | Completed | Generating Revenue | |
| 1. Seed Round | 22-Apr-2019 | $4.1M | $4.1M | Completed | Startup |
Genesis Molecular AI Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series B | ||||||||
| Series A-2 | ||||||||
| Series A-1 | ||||||||
| Series A | 9,254,372 | $0.000010 | $0.31 | $5.11 | $5.11 | 1x | $5.11 | 11.15% |
| Seed | 4,485,796 | $0.000010 | $0.06 | $0.92 | $0.92 | 1x | $0.92 | 5.4% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Genesis Molecular AI Comparisons
Industry
Financing
Details
Genesis Molecular AI Competitors (11)
One of Genesis Molecular AI’s 11 competitors is X-37, a Venture Capital-Backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| X-37 | Venture Capital-Backed | South San Francisco, CA | ||||
| Exscientia | Formerly VC-backed | Oxford, United Kingdom | ||||
| NuMedii | Formerly VC-backed | San Mateo, CA | ||||
| Numerion Labs | Venture Capital-Backed | San Francisco, CA | ||||
| Verge Labs | Venture Capital-Backed | San Francisco, CA |
Genesis Molecular AI Patents
Genesis Molecular AI Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026096998-A1 | Generating predicted 3d structures of molecular systems using generative models with equivariant attention layers | Pending | 01-Nov-2024 | ||
| WO-2026024674-A1 | Methods of treating skp2-associated cancers | Pending | 22-Jul-2024 | ||
| WO-2025179257-A1 | Generative machine learning models for protein-ligand docking | Pending | 23-Feb-2024 | ||
| WO-2025179253-A1 | Training generative machine learning models for 3d molecular structure prediction using alignment objectives | Pending | 23-Feb-2024 | ||
| WO-2025144931-A1 | Methods for treating cancer | Inactive | 27-Dec-2023 | C07D471/04 |
Genesis Molecular AI Signals
Genesis Molecular AI Investors (23)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Valera Capital | Family Office | Minority | ||
| Baker Brothers Investments | Hedge Fund | Minority | ||
| BlackRock | Asset Manager | Minority | ||
| Fidelity Management & Research Company | Asset Manager | Minority | ||
| Lilly USA | Corporation | Minority |
Genesis Molecular AI FAQs
-
When was Genesis Molecular AI founded?
Genesis Molecular AI was founded in 2019.
-
Where is Genesis Molecular AI headquartered?
Genesis Molecular AI is headquartered in San Mateo, CA.
-
What is the size of Genesis Molecular AI?
Genesis Molecular AI has 170 total employees.
-
What industry is Genesis Molecular AI in?
Genesis Molecular AI’s primary industry is Drug Discovery.
-
Is Genesis Molecular AI a private or public company?
Genesis Molecular AI is a Private company.
-
What is Genesis Molecular AI’s current revenue?
The current revenue for Genesis Molecular AI is .
-
How much funding has Genesis Molecular AI raised over time?
Genesis Molecular AI has raised $327M.
-
Who are Genesis Molecular AI’s investors?
Valera Capital, Baker Brothers Investments, BlackRock, Fidelity Management & Research Company, and Lilly USA are 5 of 23 investors who have invested in Genesis Molecular AI.
-
Who are Genesis Molecular AI’s competitors?
X-37, Exscientia, NuMedii, Numerion Labs, and Verge Labs are some of the 11 competitors of Genesis Molecular AI.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process